Abstract

BackgroundThis study aimed to explore the clinical features of gout in adult patients with glycogen storage disease type Ia (GSD Ia).MethodsNinety-five adult patients with GSD Ia admitted to Peking Union Medical College Hospital were retrospectively analysed. A clinical diagnosis of GSD Ia was confirmed in all patients through gene sequencing. All patients had hyperuricaemia; 31 patients complicated with gout were enrolled, and 64 adult GSD Ia patients with asymptomatic hyperuricaemia were selected as a control group during the same period. Clinical characteristics were analysed and compared between the two groups.ResultsThirty-one of the 95 patients had complications of gout (median age, 25 years; 11 (35.5%) females). All 31 patients had hepatomegaly, abnormal liver function, fasting hypoglycaemia, hyperuricaemia, hyperlipaemia, and hyperlacticaemia. A protuberant abdomen, growth retardation, recurrent epistaxis, and diarrhoea were the most common clinical manifestations. Among these 31 patients, 10 patients (32.3%) had gout as the presenting manifestation and were diagnosed with GSD Ia at a median time of 5 years (range, 1–14) after the first gout flare. The median age of gout onset was 18 years (range, 10–29). Fifteen of the 31 GSD Ia-related gout patients were complicated with gouty tophi, which has an average incidence time of 2 years after the first gouty flare. The mean value of the maximum serum uric acid (SUA) was 800.5 μmol/L (range, 468–1068). The incidence of gout in adult GSD Ia patients was significantly associated with the initial age of regular treatment with raw corn starch, the proportion of urate-lowering therapy initiated during the asymptomatic hyperuricaemic stage, maximum SUA level, and mean cholesterol level.ConclusionsDetermination of GSD Ia should be performed for young-onset gout patients with an early occurrence of gouty tophi, especially in patients with hepatomegaly, recurrent hypoglycaemia, or growth retardation. Early detection and long-term regulatory management of hyperuricaemia, in addition to early raw corn starch and lifestyle intervention, should be emphasized for GSD Ia patients in order to maintain good metabolic control.Trial registrationRetrospectively registered.

Highlights

  • This study aimed to explore the clinical features of gout in adult patients with glycogen storage disease type Glycogen storage disease type Ia (Ia) (GSD Ia)

  • Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disorder caused by mutations in the glucose-6-phosphatase catalytic subunit (G6PC) gene leading to a deficiency of the glucose-6-phosphatase catalytic unit (G6Pase-α) enzyme [12]

  • We retrospectively reviewed the medical records of 95 adult glycogen storage disease type Ia (GSD Ia) patients who had been admitted to Peking Union Medical College Hospital (PUMCH) between 1 January 1999 and 30 December 2018

Read more

Summary

Introduction

This study aimed to explore the clinical features of gout in adult patients with glycogen storage disease type Ia (GSD Ia). A recognized complication of hyperuricaemia (HUA), is the most common type of inflammatory arthritis in adults, caused by the deposition of monosodium urate (MSU) crystals in joints or adjacent soft tissues. Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disorder caused by mutations in the glucose-6-phosphatase catalytic subunit (G6PC) gene leading to a deficiency of the glucose-6-phosphatase catalytic unit (G6Pase-α) enzyme [12]. Mutations in this gene result in the inhibition of glucose production and accumulation of glycogen and fat in the liver, kidney, and intestine. A delayed diagnosis and inappropriate interventions can lead to many complications, such as growth failure, refractory gout, renal failure, and hepatocellular carcinoma

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call